PGT-A in IVF: the Problem With “98% Accuracy”

Описание: When IVF Marketing Moves Faster Than Science. IVF’s Most Trusted Add-On — Reexamined. PGT-A (preimplantation genetic testing for aneuploidy) is often presented as a way to improve IVF outcomes and reduce uncertainty. Many patients are told the test is “98% accurate” and broadly beneficial — especially as maternal age increases. But what does that number actually describe? And how much certainty does PGT-A really provide? 📌 Sources and studies referenced are linked below. 📌 This episode is informational, not medical advice.

https://pubmed.ncbi.nlm.nih.gov/32623... -- a 2020 study that evaluated the potential viability of embryos with low mosaicism level.

https://academic.oup.com/humrep/artic... -- a case report of a healthy baby born from a known mosaic embryo transfer.

https://www.remembryo.com/children-bo... -- report on children born from mosaic embryo transfers.

https://pubmed.ncbi.nlm.nih.gov/40578... -- A 42-year-old female patient and a 49-year-old male partner transferred three aneuploid female and one euploid male embryos and got Healthy euploid dizygotic twin birth, the twins are now nearly 7 years of age and healthy without developmental concerns.

https://pmc.ncbi.nlm.nih.gov/articles... -- a case report of a healthy live birth from a genetically “chaotic” embryo.

Class action lawsuits filed against IVF labs for PGT-A false advertising:

https://www.reproductivetimes.com/p/f...
https://bergermontague.com/cases/pgta... https://www.classaction.org/news/clas...
https://www.prnewswire.com/news-relea...